Overview

A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Status:
Completed

Trial end date:
2019-02-06

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the efficacy of Guselkumab with commercially available active comparator Fumaderm initial/Fumaderm tablets for the treatment of adult participants with moderate to severe plaque-type psoriasis who have not yet received any systemic therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen-Cilag G.m.b.H

Treatments:

Dimethyl Fumarate